Data from Mie in Mie，2013-2015 The annual sales of Chinese urban public hospitals in public hospitals is 132 billion yuan、144.7 billion yuan and 151.4 billion yuan， Sales in two years have increased by 19.4 billion yuan，The growth rate in 2015 was 4.69%，slightly decreased from 2014。

 

  4 products rising exclusive varieties have gradually appeared

 

 

  From Table 1, it can be seen that in 2015 urban public hospital Chinese patent medicine TOP10 products，The ranking increases from 4 in 2014，Danhong injection、Danshen Chuanlizzine injection、Blood Diagram injection and Shenqi Fuzheng injection，Among them, the blood sparse injection and the Zhengqi Fuzheng injection are all new TOP10 products。

 

  Highlights: Danhong injection & mdash; & mdash; Chinese medicine first patent gold winner

 

  Danhong injection liquid for two consecutive years is located in the urban public hospital Chinese patent medicine TOP10 My stake betting appproducts，stake online sports bettingIt is the first modern patent traditional Chinese medicine in China to quickly solve the lack of blood supply and ischemic infarction of the whole body.，As the exclusive product of Shandong Danhong Pharmaceutical Co., Ltd.，belonging to medical insurance category B medicine。Danhong injection is also the first Chinese medicine to win the Chinese Patent Gold Award，2010 & ldquo; Research and Development of Danhong injection & rdquo; won Shandong Province & ldquo; 2010 Science and Technology Progress Award & rdquo;。

 

 

  According to the data of the rice in rice，Among Chinese urban public hospitals，Danhong injection liquid in the past three years has shown a trend of rise，The sales of 2014 were 289.9 million yuan，Sales of 2015 were 329.693 million yuan，increased by 14.08%year -on -year。

 

  Highlight two: Bloodybath injection & mdash; & mdash;

 

  Blood Diagram injection as one of the new products of Chinese patent medicine TOP10 in urban public hospitals in 2015，It is the exclusive variety of Mudanjiang Youpu Pharmaceutical Co., Ltd.，belonging to medical insurance category B medicine。Bloodytic injection is a national traditional Chinese medicine second category with independent intellectual property rights，It is the first domestic animal compound water needle type。At the end of the end of Mudanjiang Youpu Pharmaceutical Co., Ltd., Mudanjiang Youbao Pharmaceutical Co., Ltd. used mergers and acquisitions to control Hunan Jiuzhitang Co., Ltd.，Realized leaping development，The development prospects of the blood sparse injection are considerable。

 

 

  Data from Mie in Mie，Among Chinese urban public hospitals，Blood Diagram injection in 2013-2015 sales and growth rates increased year by year。The sales of 2015 were 2177.26 million yuan，increased Stake Sports Betting11.My stake betting app52%from the previous year。

 

  Highlights 3: Shenqi Fuzheng injection & mdash; & mdash; aiming at the potential of overseas markets

 

  Shinqi Fuzheng injection is another new product of TOP10 in urban public hospitals in 2015，Is the exclusive variety of Lizhu Group Limin Pharmaceutical Factory，belonging to medical insurance category B medicine。Lizhu Group also actively carried out the registration work of Guizheng。

 

 

  Data from Mie in Mie，2013-2015 in Chinese urban public hospitals，Sales and growth rates of Zhengqi Fuzheng injection have shown a trend of rise。Sales in 2015 were 2052.86 million yuan，increased by 27.93%from 2014。

 

  Factory rankings have not changed a lot. 2 companies grow faster

 

 

  It can be seen from Table 2，2015 Urban Public Hospital Chinese Pharmaceutical TOP10 manufacturers have not changed much compared with 2014，Three companies with rising rankings，Among them, Shandong Danhong Pharmaceutical and Zhejiang Cumitter Pharmaceutical rose to a large increase，Zhejiang Cumitter Pharmaceuticals as the new TOP10 manufacturer，performance is worth looking forward to。

 

  Highlight 4: Shandong Danhong Pharmaceutical & MDASH; & MDASH; Maternal Company is listed on the market.

 

  Shandong Danhong Pharmaceutical Co., Ltd. (formerly Heze Bu Long Pharmaceutical Co., Ltd.) is a subsidiary of Shandong Buchang Pharmaceutical Co., Ltd.，It is the largest Chinese medicine injection production base in China，own Danhong injection、Dan Red Drop Injects、Fourteen varieties such as black head injection，Obtaining an authorized invention patent 1 item、Appearance patent 2 items，Acceptance of invention patents 3。Steps Pharmaceutical has now got the approval of the CSRC，It will officially land on the A -share market in the near future。This shows that the development stake betting appprospects of Shandong Danhong Pharmaceutical stake online sports bettingare very considerable。

 

 

  From Figure 5, it can be seen，2013-2015 in Chinese urban public hospitals，Shandong Danhong Pharmaceutical sales increase year by year，The sales of 2014 were 289.9 million yuan，2015 sales are 329.693 million yuan，increased by 14.08%year -on -year。Data from Mie in Mie，These sales are all contributed by the product of Danhong injection。

 

  Highlight 5: Zhejiang Kanglait Pharmaceutical & mdash; & mdash; Chinese medicine is internationalized

 

  As a 2015 Urban Public Hospital Chinese Pharmaceutical TOP10 New Factory，Zhejiang Cumitt Pharmaceutical is worthy of attention。Zhejiang Cumitter Pharmaceutical is & ldquo; key high -tech enterprises nationwide & rdquo;，Company patent product & ldquo; Kangleter injection & rdquo; is the only Chinese medicine for Chinese medicine preparations to enter the international market。2015 Cumitz's anti -cancer injection via FDA，and will conduct the third phase of clinical trials in the United States。

 

 

  From Figure 6, we can know，2013-2015，Among Chinese urban public hospitals，The sales of the sales of Zhejiang Cumitt Pharmaceutical showed a rise in the rise，The sales in 2015 were 1951.1 million yuan，increased by 1.69%year -on -year。Kangleter and Ginkgo leaves are the main varieties of the company。According to Mihin.com data, it shows，In 2015, Cumitt's sales were 1950.79 million yuan，99.98%of the company's sales，Ginkgo leaves only account for 0.02%of the share。

 

  Conclusion

 

  The annual sales of Chinese urban public hospitals in the past three years have increased year by year，2016 as the start of the start of the 13th Five -Year Plan & RDQUO;，All tasks are being promoted in an orderly manner。Whether the sales of 2016 can go to the first floor，What new changes will there be in urban public hospital Chinese medicines My stake betting appand TOP10 manufacturers，stake sports betting appIt is worth looking forward to。